Delivery of fibroblast growth factor 2 enhances the viability of cord blood-derived mesenchymal stem cells transplanted to ischemic limbs
Delivery of fibroblast growth factor 2 enhances the viability of cord blood-derived mesenchymal stem cells transplanted to ischemic limbs
复制标题
DOI：
10.1016/j.jbiosc.2011.01.003
复制
发表时间：
2011-05-01
影响因子：
2.8
通讯作者：
Kim, Byung-Soo
中科院分区：
文献类型：
--
作者：
Bhang, Suk Ho;Lee, Tae-Jin;Kim, Byung-Soo
将脐血间充质干细胞（CBMSCs）移植到缺血区域可能是治疗缺血性疾病的潜在疗法，但其疗效受到细胞存活率低的限制。我们假设，局部递送成纤维细胞生长因子2（FGF 2）到CBMSC移植部位将增强移植到缺血组织的CBMSC的活力。将人CBMSC加载到含有或不含FGF 2的纤维蛋白凝胶上，并肌内移植到无胸腺小鼠的正常或缺血后肢中。CBMSC移植结合FGF 2递送导致移植的CBMSC的显著较低的凋亡和较高的存活。增强的细胞存活可能是由于局部递送FGF 2和增强的抗凋亡因子分泌。CBMSC移植和FGF 2递送增强了宿主衍生的、血小板衍生的生长因子-β和NG 2的表达，其分别诱导内皮细胞归巢和周细胞募集，并且与单独的CBMSC移植相比，更有效地保护肌肉免于缺血性变性。将FGF 2递送到CBMSC移植部位可以提高CBMSC移植到缺血组织中的存活率。这种方法可用于改善CBMSC移植治疗缺血性疾病的血管生成效果。(C)2011年，生物技术学会，日本。All rights reserved.
Transplantation of cord blood-derived mesenchymal stem cells (CBMSCs) into ischemic regions could be a potential therapy for the treatment of ischemic disease, but its efficacy is limited by poor cell survival. We hypothesized that local delivery of fibroblast growth factor 2 (FGF2) to the site of CBMSC transplantation would enhance the viability of CBMSCs transplanted to ischemic tissues. Human CBMSCs were loaded onto fibrin gel with or without FGF2 and transplanted intramuscularly into either normal or ischemic hindlimbs of athymic mice. CBMSC transplantation combined with FGF2 delivery resulted in significantly lower apoptosis and higher survival of transplanted CBMSCs. The enhanced cell survival could be due to the local delivery of FGF2 and the enhanced secretion of anti-apoptotic factor. CBMSC transplantation and FGF2 delivery enhanced the expression of host-derived, platelet-derived growth factor-beta and NG2, which induce endothelial cell homing and pericyte recruitment, respectively, and more effectively protected muscles from ischemic degeneration when compared to CBMSC transplantation alone. FGF2 delivery to the site of CBMSC transplantation can enhance the survival of CBMSCs transplanted into ischemic tissues. This approach could be used to improve the angiogenic efficacy of CBMSC transplantation therapy for ischemic disease. (C) 2011, The Society for Biotechnology, Japan. All rights reserved.